This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. PS-341 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. This study is for patients with kidney disfunction (mild, moderate, severe or those patients requiring renal dialysis) to evaluate the highest dose that can be given safely. PS-341 is administered on Days 1, 4, 8 and 11 of a 21-day cycle as an intravenous bolus over 3-5 seconds.
Showing the most recent 10 out of 459 publications